Research in TBSI is constantly giving rise to knowledge, innovation, technologies and intellectual property with the potential to have positive societal and economic impact. We are committed to partnering with individual entrepreneurs and companies who are best placed to exploit and translate the work conducted here for the benefit of all. Licensing opportunities for intellectual property from TBSI are supported by the University’s Office of Corporate Partnership and Knowledge Exchange and a list of currently available technologies can be found here and OCPKE contacts here
Trinity has produced more spin-outs than any other Irish university and accounts for one-fifth of all spin-out companies from Irish higher education institutions. Many of the most succusful of these companies have come from the TBSI Schools including:
Inflazome was founded in 2016 by Prof. Luke O’Neil and Prof Matt Copper and based on collaborative research completed in between Trinity College and the University of Queensland. Inflazome is developing small molecule inhibitors of the inflammasome, a key biological target that regulates our body’s innate immune response and which is now associated with a wide variety of inflammatory diseases. After receiving €15 Million in Series A funding the team are rapidly advancing their therapies to clinical testing. Academic Promoters: Prof Luke O'Neil, Prof Matt Copper
Opsona Therapeutics is a leading clinical stage biopharmaceutical company focused on the treatment of autoimmune/inflammatory diseases and cancers. They are innovators in the field of innate immunity research and are actively identifying new ways to prevent and treat these diseases. Their drug discovery and development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs at their research locations in Dublin, Ireland. Academic Promoters: Kingston Mills & Luke O' Neill, School of Biochemistry & Immunology & Dermot Kelleher School of Medicine.Solvotrin
Many of the world’s most effective and widely-used medicines are acidic and, when taken as tablets, cause damage to the lining of the stomach. In the case of aspirin, the most-prescribed drug in the world, the stomach side-effects may help explain recent US research showing that 1 in 4 people with cardiovascular disease are no longer taking aspirin. Solvotrin has invented a number of technologies which solve this problem. The basis of the technology is a carrier group that promotes hydrolysis along the ideal route, leading to aspirin liberation in human blood and in response to enzymes found in the intestinal wall. Solvotrin will target the €15 billion anti-platelet market segment finor its two lead compounds. Academic promoter: Dr. John Gilmer, School of Pharmacy and Pharmaceutical Science.
TBSI welcomes engagement with all the key components of the entrepreneurial eco-system including experienced entrepreneurs interested in a new business opportunity; angel and seed investors; the venture capital community and potential senior management.